Huntsman Cancer Institute shared a post on LinkedIn:
“We’ve reached a meaningful milestone in advancing cancer care: the first three patients in the world were recently treated here with RYZ401 in a Phase 1 clinical trial.
This novel radiopharmaceutical targets somatostatin receptors, or ‘docking sites’ on neuroendocrine tumor cells-helping deliver radiation directly to cancer while sparing healthy tissue. It’s part of theranostics, an approach that brings diagnosis and treatment together in a more precise way.
Led by Heloisa S. and supported by the expertise of Jeffrey Yap and a deeply collaborative team, this work reflects what’s possible when science and care come together.
The potential impact is significant: expanding targeted radiopharmaceutical therapies to more cancer types and offering new options for patients.”
Other articles about Huntsman Cancer Institute on OncoDaily.